logo
  

Trinity Industries Completes $250 Mln Share Repurchase Program

Trinity Industries Inc. (TRN) said that it has completed the $250 million share repurchase program authorized by its Board of Directors in October 2020.

As a result, Trinity's Board has approved a new $250 million share repurchase program, effective September 9, 2021, that expires on December 31, 2022.

Trinity also declared a quarterly dividend of 21 cents per share on its $0.01 par value common stock. The quarterly cash dividend, representing Trinity's 230th consecutively paid dividend, is payable October 29, 2021, to stockholders of record on October 15, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
RELATED NEWS
Follow RTT